Finance

Lists
Why is PCVX up 30.70%?
Dive Deeper
PCVX:NASDAQ
Vaxcyte Inc
$73.82
+30.70%
(+17.34) 1D
$72.27
-2.10% (-1.55)
Pre-market
Closed: Oct 5, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PCVX...
Open
$87.21
High
$90.75
Low
$71.60
Mkt. cap
10.98B
Avg. vol.
1.34M
Volume
50.55K
52-wk high
$90.75
52-wk low
$39.87
EPS
-$7.64
Beta
1.23
Shares outstanding
148.80M
No. of employees
507
Open
$87.21
High
$90.75
Low
$71.60
Mkt. cap
10.98B
Avg. vol.
1.34M
Volume
50.55K
52-wk high
$90.75
52-wk low
$39.87
EPS
-$7.64
Beta
1.23
Shares outstanding
148.80M
No. of employees
507
News stories
From web sources and news partners
About Vaxcyte Inc
CEO-
Employees507
Founded2013
HeadquartersSan Carlos, California, United States
SectorBiotechnology
Websitevaxcyte.com
Analyst ratings
Based on 7 analysts giving stock ratings to PCVX in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for PCVX in the last 3 months.
Highest
Current $73.82
$163.00 (+120.81%)
Average
$123.71 (+67.58%)
Lowest
$75.00 (+1.60%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Buy
Reiterated
$146.00
+97.8%
10/05/2026
Joseph Stringer
Needham
Buy
Reiterated
$122.00
+65.3%
10/05/2026
Roger Song
Jefferies
Buy
Maintained
$146.00
+97.8%
10/05/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$163.00
+120.8%
10/05/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$125.00
+69.3%
10/05/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$116.00
+57.1%
08/05/2026
Tara Bancroft
TD Cowen
Buy
Maintained
$75.00
+1.6%
08/05/2026
Thomas Shrader
BTIG
Buy
Maintained
$89.00
+20.6%
07/29/2026
Umer Raffat
Evercore ISI
Buy
Maintained
-
-
05/21/2026
Unknown Analyst
Mizuho Securities
Buy
Maintained
$163.00
+120.8%
03/24/2026
Unknown Analyst
Jefferies
Buy
Maintained
$146.00
+97.8%
02/25/2026
Asad Haider
Goldman Sachs
Hold
Maintained
$67.00
-9.2%
02/26/2026
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.97 / -$2.16
+8.96%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
209.93M
242.06M
312.78M
267.85M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
32.45M
32.22M
33.07M
34.92M
Operating expense
242.38M
274.28M
345.85M
302.78M
Total operating expenses
242.38M
274.28M
345.85M
302.78M
Operating income
-242.38M
-274.28M
-345.85M
-302.78M
Other non operating income
291.00K
1.32M
-1.38M
-7.28M
EBT including unusual items
-212.83M
-246.51M
-320.62M
-284.30M
EBT excluding unusual items
-212.83M
-246.51M
-320.62M
-284.30M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-212.83M
-246.51M
-320.62M
-284.30M
Net profit margin
-
-
-
-
Earnings per share
-1.56
-1.80
-2.30
-1.97
Interest and investment income
29.26M
26.45M
26.61M
25.76M
Interest expense
-
-
-
-
Net interest expenses
29.26M
26.45M
26.61M
25.76M
Depreciation and amortization charges
-
-
-
-
EBITDA
-239.32M
-266.79M
-342.90M
-299.78M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps